6 completed, 1 terminated. 5 Phase 4, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Completed 5 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Abuse Potential: new trials by email Literature Review of Abuse Potential trials Research Report on Abuse Potential
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users Placebo, Oxycodone 20 mg, GE-IR 200 mg - Abuse Potential | Phase 4 | Completed | Arbor Pharmaceuticals, Inc. | 110 | 2022-01-31 | 2024-08-12 |
| A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem Suvorexant, Zolpidem, Seltorexant - Healthy Non-dependent, Recreational Sedative Users, Abuse Potential | Phase 1 | Completed | Janssen Research & Development, LLC | 127 | 2021-12-17 | 2025-04-27 |
| An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users Placebo, Alprazolam 2 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg - Abuse Potential | Phase 4 | Completed | Arbor Pharmaceuticals, Inc. | 86 | 2021-09-28 | 2024-08-12 |
| Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users Pregabalin 300mg, pregabalin 450 mg, Pregabalin 300 mg with oxycodone 20 mg - Abuse Potential | Phase 4 | Completed | Viatris Specialty LLC | 60 | 2021-07-27 | 2023-08-14 |
| Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg - Abuse Potential | Phase 4 | Completed | Viatris Specialty LLC | 54 | 2021-04-30 | 2023-08-14 |
| Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience gabapentin 600 mg, gabapentin 1200 mg, gabapentin 1800 mg - Abuse Potential | Phase 4 | Completed | Viatris Specialty LLC | 52 | 2021-03-29 | 2024-07-24 |
| A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users Tozadenant, Placebo oral tablet, d-amphetamine - Abuse Potential | Phase 1 | Terminated | Biotie Therapies Inc. | 26 | 2017-09-18 | 2018-08-13 |
Gabapentin (4) · Oxycodone (3) · 1-(((alpha-isobutanoyloxyethoxy)carbonyl)aminomethyl)-1-cyclohexaneacetic acid (2) · Alprazolam (1) · Dextroamphetamine (1) · Diazepam (1) · Pregabalin (1) · Zolpidem (1) · seltorexant (1) · suvorexant (1) · tozadenant (1)
Viatris Specialty LLC (3) · Arbor Pharmaceuticals, Inc. (2) · Biotie Therapies Inc. (1) · Janssen Research & Development, LLC (1)
United States (6) · Canada (1)
Dik WH NG, PhD (1) · Dik WH Ng, PhD (1) · Michael McDonnell, MD (1)